Department Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Department for BioMedical Research, University of Bern, Bern, Switzerland.
Eur J Haematol. 2022 Jan;108(1):45-51. doi: 10.1111/ejh.13710. Epub 2021 Oct 24.
A small number of retrospective studies suggest AIHA to be associated with an increased risk to suffer from thromboembolic events. However, based on these studies it remains unclear whether the complement activation per is a risk factor to develop thromboembolic events in AIHA patients. The aim of this retrospective study is to investigate the incidence of thromboembolic events and the relation to complement activation in a cohort of AIHA patients.
We included 77 patients in this study with a positive DAT and hemolytic parameters or with AIHA diagnosis based on the medical report. The included patients were screened for thromboembolic events (TEE) and have been stratified in groups with and without complement activation based on the positivity for complement in the DAT.
Of the 77 included patients, 51 (66%) had warm AIHA, 13 (17%) cold-AIHA, 5 (7%) mixed AIHA, and 8 (10%) atypical AIHA, respectively. Primary and secondary AIHA was diagnosed in 44% and 56%, respectively. Twenty patients (26%) suffered from TEE. The majority (80%) of these patients suffered from warm AIHA and 10% from cold-AIHA. Hemolysis parameters did not differ in patients with and without TEE. There was no correlation with complement activation as evidenced by a positivity for complement in the monospecific DAT with the occurrence of TEE.
AIHA is associated with an increased risk of TEE. Based on these results prophylactic anticoagulation might be considered as soon as the diagnosis of AIHA is confirmed.
少数回顾性研究表明自身免疫性溶血性贫血(AIHA)与血栓栓塞事件的风险增加相关。然而,基于这些研究,补体激活是否是 AIHA 患者发生血栓栓塞事件的危险因素仍不清楚。本回顾性研究旨在调查 AIHA 患者血栓栓塞事件的发生率及其与补体激活的关系。
我们纳入了本研究中 DAT 阳性和溶血参数阳性或基于病历诊断为 AIHA 的 77 例患者。对纳入的患者进行血栓栓塞事件(TEE)筛查,并根据 DAT 中补体的阳性情况将其分为补体激活组和非补体激活组。
在纳入的 77 例患者中,分别有 51 例(66%)为温抗体型 AIHA、13 例(17%)为冷抗体型 AIHA、5 例(7%)为混合抗体型 AIHA 和 8 例(10%)为非典型 AIHA。分别诊断为原发性和继发性 AIHA 的患者比例为 44%和 56%。20 例(26%)患者发生 TEE。这些患者大多数(80%)为温抗体型 AIHA,10%为冷抗体型 AIHA。有 TEE 患者和无 TEE 患者的溶血参数无差异。补体激活与 TEE 的发生无关,这一点可通过 DAT 中单特异性补体的阳性来证明。
AIHA 与 TEE 的风险增加相关。基于这些结果,一旦确诊 AIHA,就可以考虑预防性抗凝治疗。